Cancer immunotherapy comes of age and looks for maturity
As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.
Guardado en:
Autores principales: | Amanda Finck, Saar I. Gill, Carl H. June |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b79c612e2f44404b8f5683d98f5ab4b9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Christopher Sloas, et al.
Publicado: (2021) -
Single cell transcriptomics comes of age
por: Sarah Aldridge, et al.
Publicado: (2020) -
Bacterial Epigenomics: Coming of Age
por: Pedro H. Oliveira
Publicado: (2021) -
Euroquant at 21: “coming of age”?
por: David Unwin
Publicado: (1999) -
Correction for Oliveira, “Bacterial Epigenomics: Coming of Age”
por: Pedro H. Oliveira
Publicado: (2021)